Integrating remote cardiac telemetry to accelerate cardiovascular feasibility endpoints

Post-procedure monitoring in early cardiovascular device trials is shifting. Prolonged inpatient stays are giving way to continuous, high-fidelity remote telemetry that follows the subject after discharge. Done well, that change cuts trial overhead, shortens length of stay and still captures richer continuous safety data than intermittent follow-up visits. Done poorly, it creates Part 11 and medical-oversight gaps that monitors will find.

I'm Julio Martinez-Clark, CEO of Amavita Research Services. We run cardiovascular trials in Miami with continuous ECG telemetry in our Phase 1 unit and a growing remote-monitoring capability for protocols that extend observation past same-day discharge. This article covers how remote telemetry fits early feasibility and Phase I/II cardiovascular work, what 21 CFR Part 11 compliance requires of the data path, and how our Miami infrastructure supports both on-site and remote arms of a protocol.

Why early cardiovascular protocols are adopting remote telemetry

Early feasibility and Phase I cardiovascular device studies collect their most informative acute safety data in the hours after the procedure: rhythm, access-site status, vital-sign trends and device-specific signals. FDA's 2013 guidance on early feasibility IDEs expects careful safety observation in a small number of initial subjects, often fewer than ten, with protocol and device changes anticipated as the team learns.

Keeping every subject in a monitored bed for days is expensive and, for many catheter-based protocols, unnecessary once acute stability criteria are met. Remote cardiac telemetry lets the protocol define a same-day or short observation window on site, then continue rhythm and symptom surveillance at home for the period that matters for early readmission risk — commonly through 30 days when the endpoint or safety narrative includes post-discharge events.

The operational win is real: fewer overnight bed-days, less competition for inpatient telemetry, and a continuous dataset instead of sparse snapshot ECGs at follow-up visits. The scientific win is continuous rhythm context around symptoms that subjects report between visits.

Remote telemetry protocols that hold up in early feasibility

A remote-telemetry add-on is not a consumer wearable bolted onto a protocol. For investigational cardiovascular devices the protocol has to define:

1. What is monitored. Continuous ECG rhythm, event-triggered strips, heart-rate trends, and any device-specific signals the sponsor requires.
2. Who watches in real time. A named monitoring service or site team with escalation criteria, not an unreviewed cloud dashboard.
3. When escalation fires. Pre-specified arrhythmia thresholds, symptom triggers and contact pathways to the investigator.
4. How long monitoring runs. Tied to the safety endpoint — for example through day 7, day 14 or day 30 — not to a marketing claim about readmission reduction.
5. What becomes source data. Which strips, alerts and acknowledgments enter the eCRF or are filed as certified copies for monitoring.

We will not claim that remote telemetry alone "cuts 30-day cardiac readmissions" as a universal outcome. Readmission risk depends on the procedure, the population and the care pathway. What we will say is that continuous post-discharge rhythm data lets the study team detect and act on events that intermittent follow-up would miss, and that those data strengthen the early safety narrative sponsors take back to FDA.

21 CFR Part 11 and the remote data path

Remote monitoring systems that generate electronic records used in a clinical investigation fall under 21 CFR Part 11 expectations for trustworthiness: validation, audit trails, operational system checks, authority checks, device checks where applicable, and controlled copies for FDA inspection. Sponsors and sites share responsibility. The site cannot assume the vendor's marketing sheet equals a Part 11 package.

Questions we put in feasibility when a protocol includes remote telemetry:

• Is the system validated for the intended clinical-research use, with a validation summary the sponsor's quality team can review?
• Are user access, e-signatures and audit trails configurable and exportable?
• Who holds the certified copy of alerts and strips — sponsor, vendor or site — and how does the monitor retrieve them?
• How are time stamps synchronized across the device, the cloud and the site clock?
• What happens to data if a subject loses connectivity, removes the sensor or travels outside coverage?

Part 11 compliance is not a sticker on the hardware. It is the documented controls around creation, modification and retrieval of the electronic records the study will rely on. Amavita Research Services works to ICH-GCP E6(R3) and IAOCR GCSA certification; remote-telemetry vendors we use on a protocol have to clear the same seriousness bar as any other electronic source system on the study.

Amavita Research Services' Miami telemetry infrastructure

Our on-site foundation is the Phase 1 unit at Advanced Cardiovascular of Miami, an affiliated cardiovascular ambulatory surgery center in Kendall: 8 monitored observation beds with continuous ECG telemetry, cath-lab access under one roof, and same-day observation by design. That unit is where acute post-procedure data are captured before any remote arm begins. Details are on our Phase 1 unit overview and our early feasibility telemetry note.

Remote telemetry extends that observation window past discharge when the protocol calls for it. The site workflow we run:

• Confirm during feasibility that the remote system matches the protocol's monitoring interval, alert rules and Part 11 expectations.
• Train subjects on sensor placement, charging and symptom reporting before discharge.
• Keep investigator oversight of alerts with documented acknowledgment and escalation.
• File remote strips and alert logs as source for monitor review alongside on-site telemetry records.
• Define stop rules if remote data quality falls below protocol thresholds.

Protocols that need multi-day inpatient monitoring or intensive care still belong in a hospital setting. Remote telemetry does not replace acuity. It extends surveillance after the subject meets discharge criteria.

Endpoints remote telemetry can actually support

Used honestly, continuous remote rhythm data supports early cardiovascular feasibility endpoints such as:

• Incidence and timing of protocol-defined arrhythmias through a fixed post-procedure window.
• Time from symptom onset to investigator contact when subjects wear a monitored device.
• Adjudication packages that include continuous context around reported events, not only a follow-up ECG days later.
• Safety follow-up intensity that matches risk without keeping every subject in a bed.

Used dishonestly, remote telemetry becomes a substitute for investigator oversight or a vague claim about readmission reduction without a defined endpoint. We will not write that claim into a protocol for you. We will help you write a monitoring schedule that the site can execute and the monitor can verify.

Coordination with the rest of the study team

Remote telemetry only helps if the sponsor, CRO and site agree on who owns each alert. We prefer a written responsibility matrix before first patient in: which alerts page the site investigator, which go to a central monitoring service first, and how quickly an acknowledgment must appear in the record. Ambiguity here produces either missed escalations or alert fatigue. Both show up in monitoring findings. Building that matrix during feasibility is cheaper than rewriting it after the first subject is discharged.

Discuss the monitoring schedule early

If your early-phase cardiovascular protocol includes a post-discharge telemetry window — through 7, 14 or 30 days — bring the monitoring schedule, alert rules and vendor Part 11 package to feasibility along with the procedure description. We will map the acute window to our eight-bed telemetry unit and the remote window to a data path our quality system can stand behind. Discuss your early-phase cardiovascular protocol with Amavita Research Services through the capabilities page or meet the investigators first.